Piramal Pharma takes Yapan Bio majority for ₹76 crore
What's the deal? Piramal PharmaDealroom has a profile for this one. Try Dealroom → has acquired an additional 40.67% stake in Yapan Bio for roughly ₹76 crore, raising its holding from 33.33% to 74%. The Mumbai-based company bought 146,400 equity shares of ₹10 each in cash, turning Yapan Bio from an associate into a subsidiary.
What's the endgame? Yapan Bio, founded in 2019, is a contract development and manufacturing organisation (CDMO). It handles process development, characterisation, and Phase I/II GMP manufacturing for vaccines and biologics — capabilities Piramal wants to fold into its integrated service offering.
By the numbers: Yapan Bio's revenue has swung sharply, hitting ₹26.91 crore in fiscal 2024, ₹54.40 crore in 2025, and ₹26.34 crore in 2026. The volatility underscores why Piramal is buying control rather than growth already in hand.
Why now? Yapan Bio's acquisition followed Piramal's August 10, 2026 announcement that it planned to exercise a call option for the stake. It has since closed the transaction, disclosed under Regulation 30 of the SEBI Listing Obligations and Disclosure Requirements.
The signal: The move deepens Piramal's push into large-molecule biologics, a segment where CDMOs are racing to add complex therapy manufacturing. By taking majority control, Piramal bets on owning that pipeline rather than partnering for it.
Read more: Business Upturn
Image credit: Generated with Gemini
